Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EntreMed peptide progressing well
Proteinase activated receptor (PAR-2) is a cell surface receptor known to play a critical role in mediating acute and chronic inflammation. EntreMed is developing a peptide that blocks
Proteinase activated receptor (PAR-2) is a cell surface receptor known to play a critical role in mediating acute and chronic inflammation. EntreMed is developing a peptide that blocks
The research agreement between ChemGenex and Vernalis, which was signed in August 2004, has a value of approximately A$2 million ($1.6 million) in the first year following milestone
PDE10A is a class of phosphodiesterases that degrades cAMP and cGMP, molecules responsible for improving the function of many different cells in the body, including neurons. By inhibiting
The deal will transform Medco into the industry’s most comprehensive full-service pharmacy benefit provider, offering a broad spectrum of prescription medicines and integrated clinical services and support. Specialty
Shire has received a Paragraph IV notice letter from Teva Pharmaceuticals USA advising of the filing of an abbreviated new drug application (ANDA) for its mixed amphetamine product.
The IT giant revealed plans to offer its data-mining algorithms, machine-learning and other software techniques as part of the ongoing research to find more effective HIV vaccines. Some
The discussion at the meeting of the Arthritis and Drug Safety and Risk Management Advisory Committees affirmed the safety of Aleve and distinguished the safety profile of naproxen,
The 360-patient trial will be monitored by the World Health Organization (WHO), UNICEF and the Pasteur Institute, and follows Millenia Hope’s recent success with three efficacy trials. The
The European approval covers the use of Azilect (known in the US as Agilect) both as monotherapy in patients with early Parkinson’s disease (PD) and as adjunct treatment
The FDA granted approval for Mayne’s abbreviated new drug application (ANDA) for carboplatin 600mg/60ml solution in November 2004. Carboplatin is used for the initial treatment of advanced ovarian